Childrens National Hospital

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Sickle cell disease4 trials
• Childhood cancers3 trials
• Aortic stenosis2 trials
• Familial hypercholesterolaemia2 trials
• Heart failure2 trials
• Neuroblastoma2 trials
• Acute lymphoblastic leukaemia1 trial
• Glioblastoma1 trial
• Kidney cancer1 trial
• Myocarditis1 trial
• Sarcoma1 trial
• Tourette syndrome1 trial

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 43 trials
• Phase 11 trial

Status

• Active, not recruiting5 trials
• Recruiting4 trials
• Completed2 trials
• Not yet recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals8 trials
• Children's National Research Institute1 trial
• Emalex Biosciences Inc.1 trial
• Incyte Corporation1 trial
• Pfizer1 trial

Running trials

• Recruiting

  Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  NCT07172958· Phase 1· Children's National Research Institute· Source

  Contact: Holly Meany, MD

• Recruiting

  Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

  NCT06597006· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Desiree Tobechukwu Nwanze

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

  NCT06597019· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Carlos Jesus Carhuas

• Recruiting

  A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  NCT06439082· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Taylor Quinn

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Active, not recruiting

  A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

  NCT05295290· Phase 4· Pfizer· Source

• Recruiting

  Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

  NCT04657822· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

  NCT03876769· Phase 2· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Heart failure2 recruiting
• Childhood cancers1 recruiting
• Kidney cancer1 recruiting
• Neuroblastoma1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

  NCT03938454· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

  NCT03474965· Phase 2· Novartis Pharmaceuticals· Source